[Skip to Content]
Navigation
Home > Medical Directory > What is Scleroderma? > Scleroderma Research > Treatments > Clinical Trials

Completed: Awaiting Results

Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer

Psychological Treatments for Scleroderma

Study closed. Awaiting results.
Psychological Treatments for Scleroderma. This study will examine the effectiveness of two psychological treatment approaches designed to help people who have scleroderma with three important areas of daily living: pain, depression, and distress about changes in appearance. Study dates 2001-2004. ClinicalTrials.gov

Sildenafil (Viagra) in Treatment of Pulmonary Hypertension

Study closed. Awaiting results.
Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension. To assess the safety of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1 and 2) To assess the efficacy after 12 weeks of treatment of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1). March, 2009. clinicaltrials.gov.

SLx-2101 in Secondary Raynaud's

Study closed. Awaiting results.
Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease. A Randomized, Double Blind, Placebo-Controlled, Cross-Over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease. December, 2008. clinicaltrials.gov.
Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease. SLx-2101 is a novel, long-acting PDE-5 inhibitor being developed for the management of diseases associated with vascular dysfunction such as Raynaud's. The company has also completed four Phase 2a clinical studies in hypertension, Raynaud's disease and erectile dysfunction, all of which further demonstrated the efficacy of the compound. Surface Logix Inc. 2008. (Also see: Raynaud's Treatments)

See Also

Sjögren's Treatments & Clinical Trials
Scleroderma Medical News

Scleroderma Symptoms (treatments are listed for each symptom)
 
Go to Scleroderma Clinical Trials: Inconclusive
 

SCLERO.ORG is operated by the International Scleroderma Network, which is a full-service U.S. nonprofit 501(c)(3) established in 2002. We provide stellar worldwide research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. Donate or Shop Now.

Questions? Post a message in Sclero Forums or email us directly at isn@sclero.org. Or call our Scleroderma Hotline (English only), Toll Free in U.S. 1-800-564-7099 or Direct at 1-952-831-3091. Ask for our Welcoming Email.

Our headquarters postal mailing address is: International Scleroderma Network (ISN), 7455 France Ave So #266, Edina, MN 55435-4702, United States.

The most important thing in the world to know about scleroderma...is sclero.org!
Home   Medical   News   Sclero Forums   Support   Translations  Donate or Shop
Copyright 1998-2014, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.